Don't Miss a Beat: ESC Heart Failure Association Preview
In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.
With the publishing of a new expert consensus decision pathway in late April and the European Society of Cardiology (ESC)’s Heart Failure Association (HFA) beginning on May 20, heart failure with preserved ejection fraction (HFpEF) has been in the spotlight for the cardiology community through May 2023.
Published in the Journal of the American College of Cardiology on April 19, 2023, the 44-page expert consensus decision pathway is broken down into 9 sections and was published with the intent of informing the development of various tools that accelerate real-time use of clinical policy at the point of care.1
Scheduled to take place in Prague and virtually from May 20-23, 2023, the ESC HFA meeting, which is billed as the world’s leading heart failure event, features more than 1000 abstracts and 300 sessions dedicated to showcasing the latest in heart failure management. Headlining the meeting is the late-breaking clinical data expected to be presented, including results of the PARAGLIDE trial and baseline data from FINEARTS-HF.
Perhaps the most anticipated data from the meeting, PARAGLIDE trial was launched by Novartis with the intent of evaluating changes in NT-proBNP, safety, and tolerability of sacubitril/valsartan (Entresto) in HFpEF patients with a worsening heart failure event. With more than 450 enrolled patients, the trial, which is expected to be presented by Rob Mentz, MD, associate professor of medicine and chief of the Heart Failure Section at the Duke University School of Medicine, on May 21, 2023, will provide clinicians with a more holistic interpretation of the effects of sacubitril/valsartan across the spectrum of ejection fraction.2
FINEARTS-HF, which will be presented by Scott Solomon, MD, director of the Clinical Trials Outcomes Center at Brigham and Women’s Hospital, will offer clinicians with a look behind the curtain at Bayer’s heart failure trial for finerenone (Kerendia). With approval for chronic kidney disease in type 2 diabetes from the US Food and Drug Administration in July 2021, many in the community are hopeful finerenone could be the next novel agent to expand its foothold in treatment algorithms for cardiometabolic disease.3
In this episode of Don’t Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, cardiologist and co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, and Stephen Greene, MD, associate professor of medicine and advanced heart failure specialist at the Duke University School of Medicine, sit down at ESC HFA to discuss key takeaways from the expert clinical decision pathway and preview data scheduled to be presented during the meeting.
All episodes of Don’t Miss a Beat are available in an audio-only format on Spotify and Apple Podcasts.
Editor's note: The slides in the video version of this podcast were obtained from the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction.
References:
- Campbell P. JACC documents offer overview of diagnosis, management, challenges of HFpEF. HCP Live. April 22, 2023. Accessed May 19, 2023. https://www.hcplive.com/view/jacc-documents-offers-overview-of-diagnosis-management-challenges-of-hfpef.
- Changes in NT-probnp, safety, and tolerability in HFPEF patients with a WHF event (HFpEF decompensation) who have been stabilized and initiated at the time of or within 30 days post-decompensation (Paraglide-HF) - full text view. Full Text View - ClinicalTrials.gov. Accessed May 19, 2023. https://clinicaltrials.gov/ct2/show/NCT03988634.
- Campbell P. Finerenone (Kerendia) approved for chronic kidney disease associated with type 2 diabetes. HCP Live. July 9, 2021. Accessed May 19, 2023. https://www.hcplive.com/view/finerenone-kerendia-approved-chronic-kidney-disease-associated-with-type-2-diabetes.
Disclosures:
Vaduganathan reports having received funding for consulting or research grants from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others.
Greene reports having received funds for consulting or research grants from Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.
